Hemab Therapeutics Holdings COAG Insider Ownership

Updated Oct 10, 2026

Over the past 12 months, Hemab Therapeutics Holdings insiders bought $55.46 million of stock on the open market (2.97Mn shares) and made no open-market sales.

• Among Hemab Therapeutics Holdings' insiders, the largest open-market purchases in the past 12 months were by Ra Capital Management, L.P. (10% owner), totaling $55.46 million (2.97Mn shares), most recently on June 16, 2026.
• Outside the open market, Hemab Therapeutics Holdings insiders acquired 9.02Mn shares through option exercises and conversions over the past 12 months.
• Per Business Quant data, Hemab Therapeutics Holdings insiders hold 10.63Mn shares in total based on their latest Form 4 filings, or 22.75% of the 46.71Mn shares outstanding; that total is unchanged from 10.63Mn shares at the end of Q2 2026.
• Indirect holdings, through trusts, partnerships, family members and other entities, make up 60.65% (6.44Mn shares) of Hemab Therapeutics Holdings' insider total, with the other 39.35% (4.18Mn shares) held directly.
• Per Business Quant, 2 insiders of COAG hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
• COAG's largest insider holders by reported holdings are Ra Capital Management, L.P. (10% owner, 6.44Mn shares) and Novo Holdings A/S (10% owner, 4.18Mn shares).
• Ra Capital Management, L.P. alone accounts for 60.65% of the shares held by Hemab Therapeutics Holdings insiders.
• A total of 7 Form 4 filings with transactions in Hemab Therapeutics Holdings stock were made over the past 12 months, by 3 insiders.
• Insider figures for COAG include Form 4 filings through September 25, 2026.